Black Diamond Therapeutics, Inc.
BDTX
$2.02
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.73% | -14.26% | -33.66% | -32.11% | -57.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.16% | -27.22% | -43.85% | -39.45% | -39.36% |
| Operating Income | 10.16% | -120.65% | 43.85% | 39.45% | 39.36% |
| Income Before Tax | 6.21% | -115.98% | 5.44% | 45.38% | 46.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.21% | -115.98% | 5.44% | 45.38% | 46.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.21% | -115.98% | 5.44% | 45.38% | 46.95% |
| EBIT | 10.16% | -120.65% | 43.85% | 39.45% | 39.36% |
| EBITDA | 9.79% | -120.57% | 43.95% | 39.64% | 39.51% |
| EPS Basic | 7.10% | -115.82% | 6.23% | 45.77% | 48.50% |
| Normalized Basic EPS | 7.14% | -115.82% | 53.01% | 45.79% | 48.49% |
| EPS Diluted | 9.11% | -116.33% | 6.23% | 46.43% | 47.37% |
| Normalized Diluted EPS | 7.14% | -116.11% | 53.01% | 45.79% | 48.49% |
| Average Basic Shares Outstanding | 0.99% | 1.01% | 0.85% | 0.75% | 2.99% |
| Average Diluted Shares Outstanding | 0.99% | -0.76% | 0.85% | 0.75% | 2.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |